Dr Meghan Armstrong, PHARMD | |
456 Daniel Webster Hwy, Merrimack, NH 03054-3699 | |
(603) 424-1120 | |
Not Available |
Full Name | Dr Meghan Armstrong |
---|---|
Gender | Female |
Speciality | Pharmacist |
Location | 456 Daniel Webster Hwy, Merrimack, New Hampshire |
Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
Identifier | Type | State | Issuer |
---|---|---|---|
1144825696 | NPI | - | NPPES |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
183500000X | Pharmacist | PHCY00868 (New Hampshire) | Primary |
Mailing Address | Practice Location Address |
---|---|
Dr Meghan Armstrong, PHARMD 456 Daniel Webster Hwy, Merrimack, NH 03054-3699 Ph: (603) 424-1120 | Dr Meghan Armstrong, PHARMD 456 Daniel Webster Hwy, Merrimack, NH 03054-3699 Ph: (603) 424-1120 |
News Archive
The research was conducted over a period of six months with a group of 36 patients in the Hemodialysis Unit of the General University Hospital of Alicante and three nurses who had received training in solution-focused communication.
A new pilot study by US researchers demonstrates an alternative approach to long-lasting disinfection against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) by using cationic phenylene ethynylene polymers and oligomers (i.e., conjugated electrolytes). The paper is currently available on medRxiv* preprint server.
Regado Biosciences, Inc., a privately held company leading the development of antithrombotic aptamers with active control agents, announced that Chris Rusconi, PhD, Senior Vice President, Chief Scientific Officer and Steven Zelenkofske, DO, FACC, Senior Vice President , Chief Medical Officer presented an abstract at the American College of Cardiology on Monday, March 15, 2010 in Atlanta, Georgia.
In a recent and timely paper, currently available on the bioRxiv preprint server, researchers from Israel and France demonstrated how in vitro evolution of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) receptor-binding domain (RBD) follows contagious mutation spread – but can also generate an efficient infection inhibitor.
Impliant, Inc., a developer of novel motion-sparing alternatives to traditional spinal fusion surgery, announced today that it conducted the first two implantations of its TOPS VersaLink System, the newest addition to its product portfolio.
› Verified 7 days ago
Gregory Vestal, RPH Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 570 Daniel Webster Hwy, Merrimack, NH 03054 Phone: 603-424-4519 | |
Stephen James Deminico, Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 615 Daniel Webster Hwy, Merrimack, NH 03054 Phone: 603-423-9330 Fax: 603-423-9336 | |
Lauren Herrick West, RPH Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 570 Daniel Webster Hwy, Merrimack, NH 03054 Phone: 603-424-4519 | |
Renan Moretta, Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 416 Daniel Webster Hwy, Merrimack, NH 03054 Phone: 603-424-4833 Fax: 603-424-4578 | |
Mr. Brad A Valenti, RPH Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 7 Continental Blvd, Merrimack, NH 03054 Phone: 603-429-0759 Fax: 603-429-0813 | |
Nancy Delaney, Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 456 Daniel Webster Hwy, Merrimack, NH 03054 Phone: 603-424-1120 |